Invention Grant
US08648044B2 FKBP52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
有权
FKBP52-tau相互作用作为治疗涉及tau功能障碍的神经障碍的新型治疗靶点
- Patent Title: FKBP52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
- Patent Title (中): FKBP52-tau相互作用作为治疗涉及tau功能障碍的神经障碍的新型治疗靶点
-
Application No.: US13497907Application Date: 2010-09-24
-
Publication No.: US08648044B2Publication Date: 2014-02-11
- Inventor: Etienne Baulieu , Beatrice Chambraud
- Applicant: Etienne Baulieu , Beatrice Chambraud
- Applicant Address: FR Paris
- Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
- Current Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
- Current Assignee Address: FR Paris
- Agency: Whitham, Curtis, Christofferson & Cook, P.C.
- Priority: EP09305893 20090924; EP10305074 20100122
- International Application: PCT/EP2010/064115 WO 20100924
- International Announcement: WO2011/045166 WO 20110421
- Main IPC: A61K38/43
- IPC: A61K38/43 ; A61K38/00 ; A61K38/16
Abstract:
Candidate compounds for use in neuro-protection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease) are identified from a direct interaction between proteins FKBP52 and Tau. The method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction includes determining the ability of a candidate compound, to modulate binding between a Tau polypeptide and a FKBP52 polypeptide, and selecting positively the candidate compound that modulates binding.
Public/Granted literature
Information query
IPC分类:
